Perceptive Advisors LLC boosted its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 429.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,821,102 shares of the biotechnology company’s stock after buying an additional 3,100,000 shares during the period. Perceptive Advisors LLC owned 14.82% of ADMA Biologics worth $12,266,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ADMA. Iguana Healthcare Management LLC increased its position in ADMA Biologics by 276.7% during the third quarter. Iguana Healthcare Management LLC now owns 565,000 shares of the biotechnology company’s stock worth $1,740,000 after buying an additional 415,000 shares during the period. Geode Capital Management LLC increased its position in ADMA Biologics by 420.3% during the fourth quarter. Geode Capital Management LLC now owns 112,000 shares of the biotechnology company’s stock worth $359,000 after buying an additional 90,474 shares during the period. Broadfin Capital LLC acquired a new position in ADMA Biologics during the fourth quarter worth approximately $3,538,000. Stonepine Capital Management LLC acquired a new position in ADMA Biologics during the fourth quarter worth approximately $217,000. Finally, Consonance Capital Management LP increased its position in ADMA Biologics by 164.3% during the fourth quarter. Consonance Capital Management LP now owns 3,367,635 shares of the biotechnology company’s stock worth $10,810,000 after buying an additional 2,093,702 shares during the period. 52.04% of the stock is currently owned by institutional investors.
Several research analysts have commented on the company. Maxim Group set a $8.00 price target on ADMA Biologics and gave the stock a “buy” rating in a research report on Monday, March 5th. Raymond James Financial raised ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research report on Tuesday, November 14th.
About ADMA Biologics
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.